Infliximab
Infliximab biosimilar shows positive results in hidradenitis suppurativa treatment
Remicade, Stelara have similar speed of onset in Crohn’s
Patients with Crohn’s disease who were biologic naive had similar rates of clinical remission and speed of onset whether they were treated with Remicade or Stelara, according to study results.
Remicade, Stelara have similar speed of onset in Crohn’s
Patients with Crohn’s disease who were biologic naive had similar rates of clinical remission and speed of onset whether they were treated with Remicade or Stelara, according to study results.
Biosimilar uptake varies by drug class, practice type, hospital ownership status
Biosimilar use among Medicare fee-for-service beneficiaries seems to depend most on practice setting and hospital ownership status, with few patient or physician characteristics linked to usage, according to data in JAMA Network Open.
Therapeutic drug monitoring not superior to standard of care in achieving remission
Therapeutic drug monitoring, in which treatments were individually assessed and reviewed, failed to improve remission for patients with a variety of rheumatic diseases who started infliximab, according to a speaker at ACR Convergence.
Entyvio, Remicade effective in checkpoint inhibitor-induced enterocolitis
Biologic therapies achieve high response in treatment of hidradenitis suppurativa
European Commission expands approved indications for subcutaneous infliximab biosimilar
The European Commission has extended approval for Celltrion Healthcare’s subcutaneous infliximab biosimilar to treat adults with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.
Home Remicade infusions linked with suboptimal outcomes in IBD
Patients with inflammatory bowel disease who received home infusions of Remicade had higher rates of nonadherence and discontinuation of the drug, according to study results.
Biosimilar uptake still limited in the U.S.
The European Medicines Agency approved the first biosimilar in Europe in 2006. It was almost 10 years before the United States followed. Despite potential savings for payers and patients, biosimilar uptake in the U.S. remains limited.